Key takeaways
- Merck stock (NYSE: MRK) jumped about 13% on Aug. 19, 2026, closing near $152 (session high ~$153.50) after Merck and Moderna said intismeran autogene plus Keytruda met Phase 3 endpoints in adjuvant melanoma trial INTerpath-001. Volume topped 32 million shares — roughly double a typical day.
- The read-through for MRK is Keytruda lifecycle extension, not a standalone vaccine royalty story. Keytruda plus Keytruda Qlex generated $8.37 billion in Q2 2026 sales — about 50.4% of Merck’s $16.61 billion quarterly revenue. A registrational combo win protects the franchise ahead of 2028 patent pressure.
- Wall Street consensus had not priced the move: pre-rally average price target near $136, high target $155 — MRK traded through the high before the bell finished. Full hazard ratios from the interim analysis were not in the press release; overall survival data is still pending.
Merck stock did not rip because Wall Street discovered a new biotech. It ripped because the company’s earnings engine got a Phase 3 proof point that Keytruda can win as part of a combination — not just as monotherapy — in high-risk melanoma after surgery. Moderna shares absorbed more of the speculative premium on Aug. 19; MRK absorbed the “protect the cash cow” premium. Same press release, two different balance sheets.
What Merck stock did on Aug. 19
MRK opened near $146.94, traded between roughly $144.90 and $153.50, and settled around $152.20 — up about $17 from the prior close near $135.17. That is a ~12–13% one-day gain and a market-cap swing measured in tens of billions of dollars on a name investors usually treat as a defensive pharma hold.
Record intraday territory matters for index funds and passive healthcare sleeves that weight MRK heavily. Merck is not a meme ticker; when it moves double digits, pension allocators notice.
The Phase 3 catalyst — INTerpath-001
Merck and Moderna announced topline results at 6:45 a.m. EDT Aug. 19 from the Phase 3 INTerpath-001 trial: intismeran autogene (V940 / mRNA-4157) plus Keytruda versus Keytruda alone in 1,137 patients with completely resected stage IIB–IV cutaneous melanoma who had not received prior systemic therapy.
Endpoints hit at a pre-specified interim analysis:
- Primary: recurrence-free survival (RFS) — statistically significant and clinically meaningful improvement vs Keytruda monotherapy
- Key secondary: distant metastasis-free survival (DMFS) — same verdict
Phase 2 follow-up (KEYNOTE-942, five-year data at ASCO 2026) had already shown hazard ratios near 0.51 for recurrence or death and 0.411 for distant metastasis or death favoring the combo. Phase 3 confirms the signal at seven times the patient count — the dataset regulators want for filing.
Primary source: Merck press release on INTerpath-001. Trial context for the partner stock move: Moderna stock on the same Phase 3 win.
Why Keytruda math dominates MRK
Intismeran is individualized — tumor tissue sequenced, neoantigens predicted, mRNA manufactured per patient. Operationally complex, commercially interesting, but still early in revenue terms. Keytruda is today:
- Q2 2026 Keytruda + Keytruda Qlex sales: $8.37 billion
- Share of Merck total revenue: ~50.4% of $16.61 billion
- Broader oncology portfolio: still growing, but nothing matches pembrolizumab scale
Merck stock trades as a Keytruda duration play wrapped in a diversified pharma label. A Phase 3 win that keeps pembrolizumab at the center of adjuvant melanoma — now as combo anchor — extends the narrative that MRK can compound through the late 2020s even as LOE headlines loom.
Patent cliff and combination strategy
Keytruda’s U.S. composition patent exposure around 2028 is the bear case every MRK holder knows by heart. Combination regimens, new indications, and follow-on formulations (Keytruda Qlex subcutaneous) are Merck’s answer — not a single magic patent extension, but a layered defense.
Intismeran plus Keytruda in adjuvant melanoma is the first Phase 3 proof that an individualized neoantigen therapy can beat Keytruda alone in a registrational setting. If approved, Merck sells more Keytruda vials per patient course and owns half the combo economics with Moderna. Barclays has floated peak melanoma sales near $3 billion for the regimen — small vs Keytruda’s current run rate, but a template for NSCLC, bladder, and renal trials already enrolling under the INTerpath banner.
Merck stock vs Moderna stock on the same headline
Same 6:45 a.m. release, different beta:
- Moderna (MRNA): smaller revenue base, Covid hangover, oncology as survival narrative — stock moved double-digit to triple-digit percentages on optionality
- Merck (MRK): mega-cap, dividend holder base, Keytruda already priced as blockbuster — stock moved low-teens on franchise protection
MRK’s move is “estimate revisions incoming.” MRNA’s move is “company re-rating possible.” Neither is wrong; they are different instruments on the same clinical event.
Analyst targets are suddenly stale
Before Aug. 19, consensus snapshots clustered near:
- Average target: ~$136 (roughly 11% below the intraday price after the rally)
- Median target: ~$140–141
- High target: ~$155 (Scotiabank’s Louise Chen among the bulls — MRK traded through it)
- Ratings mix: heavily Buy/Strong Buy, with a handful of Holds and rare Sells
When the high target becomes the opening print, the next catalyst is analyst note day — Morgan Stanley, Wells Fargo, RBC, and others reworking models to include adjuvant melanoma approval probability and out-year combo revenue. Merck also raised full-year revenue guidance on recent earnings, which gave the tape a fundamental floor before oncology headlines hit.
Nine trials beyond melanoma
Merck and Moderna’s INTerpath program spans nine Phase 2 and Phase 3 studies across melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma. NSCLC Phase 3 trials INTerpath-002 (completely resected) and INTerpath-009 (resectable after neoadjuvant chemo plus Keytruda) are enrolling; INTerpath-014 in high-risk stage I NSCLC recently initiated.
Merck stock at $152 embeds optimism that melanoma is the first domino, not the only domino. A miss in lung would hurt; a win would multiply the addressable Keytruda combination market.
What MRK holders watch before buying the rip
Checklist for the next 90 days:
- Full data presentation at an upcoming medical congress — event counts, hazard ratios, subgroup cuts
- Overall survival from INTerpath-001 — trial continues; OS is the label that moves guidelines
- FDA/EMA filing timeline — companies said they will engage regulators; no date yet
- Analyst estimate revisions — stale $136 consensus must catch up or the stock consolidates
- Manufacturing scale for individualized mRNA — per-patient production is not Keytruda bulk fill-finish
Merck stock is not a lottery ticket on one melanoma readout. It is a bet that Wednesday’s data extends the Keytruda decade. If you already own MRK for the dividend and oncology moat, Aug. 19 validated the thesis. If you chase +13% after the print, you are paying for approvals and lung cancer readouts not yet in the label.
Market commentary only. MRK prices, analyst targets, and clinical timelines change. Confirm current quotes and Merck/Moderna disclosures before trading. Not investment or medical advice.
